Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization.

Conclusions: Sorafenib was as effective as bevacizumab in the regression of corneal neovascularization. The effect of sorafenib seems to be dose-dependent. The low doses and twice a day administration are important advantages of sorafenib. PMID: 32338080 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32338080?dopt=Abstract

Source: Cutaneous and Ocular Toxicology - April 25, 2020 Category: Toxicology Authors: Yildirim H, Aydemir O, Balbaba M, Özercan İH, Ilhan N Tags: Cutan Ocul Toxicol Source Type: research

More News: Avastin | Statistics | Study | Toxicology